New obesity drug combo tested for safety in 176-Person trial
Disease control
Completed
This study tested whether a new drug called VTX3232, taken alone or with the weight-loss drug semaglutide, is safe for people with obesity. About 176 adults with a BMI between 30 and 42 took part. The main goal was to check for side effects over 12 weeks of treatment.
Phase: PHASE2 • Sponsor: Zomagen Biosciences Ltd. • Aim: Disease control
Last updated May 01, 2026 15:57 UTC